CHK1 INHIBITION RESTORES INOTUZUMAB OZOGAMICIN CITOTOXICITY IN CD22-POSITIVE CELLS EXPRESSING MUTANT P53

E.; M. MASSIMINO; C. ROMANO; M.S. PENNISI; S. STELLA; S. VITALE; A. FIDILIO; L. MANZELLA; N. PARRINELLO; F. STAGNO; G. PALUMBO; A. ROMANO; F. DI RAIMONDO; P. VIGNERI

doi:10.54517/jbrha6455

Publication Frequency

Quarterly since 2025

Journal Articles

Search scope

Journal Center

Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

more

Volume Arrangement

2025

Vol 39, No 3 (2025)

Vol 39, No 2 (2025)

Vol 39, No 1 (2025)

Featured Articles

Macrophages in the pathogenesis of psoriasis and anti-psoriatic nanotherapies

Psoriasis is a common, chronic, and inflammatory skin disease. Macrophages account for about 61.3% of the inflammatory cells infiltrating psoriatic lesions. Modulating macrophage polarization, inhibiting their infiltration, and targeting the secretion of inflammatory factors and associated inflammatory pathways by these cells can alleviate psoriasis symptoms and inflammation. Moreover, nanomaterials as novel drug carriers, offer unique advantages such as large surface area, easy modification, high biocompatibility, good biodegradability, enhanced systemic adsorption, etc. Nanomaterials have great potential for efficient drug delivery and release, as well as improving therapeutic efficacy while reducing adverse effects. By systematically addressing the role of macrophages in psoriasis pathogenesis and the potential of nanomaterials in treating psoriasis through modulating macrophages, this review enhances our understanding of the disease mechanism and holds promise for novel therapeutic breakthroughs and advancements in the future treatment of psoriasis.

CHK1 INHIBITION RESTORES INOTUZUMAB OZOGAMICIN CITOTOXICITY IN CD22-POSITIVE CELLS EXPRESSING MUTANT P53

Article ID: 6455
Vol 32, Issue 4S1, 2018

DOI: https://doi.org/10.54517/jbrha6455

Received: 8 September 2018; Accepted: 8 September 2018; Available online: 8 September 2018; Issue release: 8 September 2018

Abstract

Inotuzumab ozogamicin (IO) is an anti-CD22 calicheamicin immunoconjugate that has been recentlyapproved for the treatment of relapsed or refractory B-Acute Lymphoblastic Leukemia (r/r B-ALL).We employed both immortalized and primary cells derived from CD22-positive lymphoproliferativedisorders to investigate the signaling pathways contributing to IO sensitivity or resistance.

References

Supporting Agencies

This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Editor-in-Chief

Dr. Fabio Malavasi

Medical Genetics, University of Torino Medical School, Italy

Co-Editor-in-Chief

Prof. Marcello Iriti

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy

Indexing & Archiving

News & Announcements

2025-02-01

Notice of Change in Publication Schedule

In addition to the first issue that has already been published by the original publisher, there will be four more issues released this year, with scheduled publication dates in March, June, September, and December respectively.

2025-01-21

Notice: Ownership Transfer of the Journal

Starting from Volume 39 Issue 2 (2025), the ownership of Journal of Biological Regulators and Homeostatic Agents (ISSN: 0393-974X (P); 1724-6083 (O)) will be transferred from Biolife Sas to Asia Pacific Academy of Science Pte. Ltd. As of 21 January 2025, authors should make submissions to the new journal system and follow the author guidelines. Asia Pacific Academy of Science Pte. Ltd. will take over the publication of manuscripts being processed.

More Announcements...